Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller, Nicholas Arthur Butowski, David Dinh Tran et al. · The Lancet Oncology · 2017
Cited by 1,134 works. doi:10.1016/s1470-2045(17)30517-x Open-access PDF
Authors
- Michael Weller
- Nicholas Arthur Butowski
- David Dinh Tran
- Lawrence David Recht
- Michael K. Lim
- Hal W. Hirte
- Lynn Stuart Ashby
- Laszlo L. Mechtler
- Samuel Aaron Goldlust
- FABIO MASSAITI IWAMOTO
- Jan Drappatz
- Donald M. O’Rourke
- Mark Ka Wong
- Mark G. Hamilton
- Gaetano Finocchiaro
- James Perry
- Wolfgang Wick
- Jennifer Green
- Yi He
- Christopher D. Turner
References
- Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
- MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials
- The Somatic Genomic Landscape of Glioblastoma
- Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
- Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
- Glioma